Clicky

Eiger BioPharmaceuticals, Inc.(EIGR)

Description: Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a portfolio of late-stage drugs for orphan diseases. It offers Sarasar, which is used for the treatment of hepatitis delta; Exendin that is used for the treatment of hypoglycemia; and Bestatin, which is used for the treatment of pulmonary arterial hypertension and lymphedema. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is based in Palo Alto, California.


Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Hypertension Hepatitis Specialty Drugs Pulmonary Arterial Hypertension Pulmonary Hypertension Orphan Disease Hypoglycemia Treatment Of Hepatitis Lymphedema Treatment Of Hypoglycemia

Home Page: www.eigerbio.com

EIGR Technical Analysis

2155 Park Boulevard
Palo Alto, CA 94306
United States
Phone: 650 272 6138


Officers

Name Title
Mr. David A. Cory M.B.A., MBA, R.Ph, R.Ph. Bus. Founder, Pres, CEO & Director
Dr. Jeffrey S. Glenn M.D., Ph.D. Scientific Founder & Independent Director
Mr. Sriram Ryali M.B.A. Chief Financial Officer
Mr. Eldon C. Mayer III, M.B.A. Exec. VP & Chief Commercial Officer
Mr. Christopher A. Kurtz Chief Technical Officer
Mr. Erik Atkisson Gen. Counsel, Corp. Sec. & Chief Compliance Officer
Dr. Ingrid C. Choong Sr. VP of Clinical Devel.
Dr. Stephana E. Patton J.D., Ph.D. Consultant
Mr. Rich Franco M.B.A. Sr. VP of Regulatory Affairs
Dr. Colin Hislop M.D. Sr. VP of Clinical & Devel. Operations

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.7598
Price-to-Sales TTM: 3.5514
IPO Date: 2014-01-30
Fiscal Year End: December
Full Time Employees: 54
Back to stocks